Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728892 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4GPR139SLC6A3 | |
| SCHEMBL1727565 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4GPR139SLC6A3 | |
| Hydrochloric Acid SCHEMBL2719228 | 0.98 | SLC6A2 (0.44) | SLC6A2SLC6A4GPR139SLC6A3 | |
| Hydrochloric Acid SCHEMBL14737983 | 0.98 | SLC6A2 (0.44) | SLC6A2SLC6A4GPR139SLC6A3 | |
| Hydrochloric Acid SCHEMBL16989095 | 0.98 | SLC6A2 (0.44) | SLC6A2SLC6A4GPR139SLC6A3 | |
| SCHEMBL21801025 | 0.90 | SLC6A2 (0.42) | SLC6A2 | |
| SCHEMBL4550413 | 0.86 | CETP (0.44) | — | |
| SCHEMBL16233093 | 0.86 | DUT (0.40) | SLC6A2SLC6A4 | |
| SCHEMBL24588079 | 0.85 | TRPM8 (0.41) | SLC6A2 | |
| SCHEMBL760742 | 0.85 | TRPM8 (0.41) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002452-A1 | BICYCLOPENTANE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2025-01-02 | — | — | US | disclosed |
| EP-4479377-A1 | NEW BICYCLOPENTANE DERIVATIVES | Icagen, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118829626-A | Novel dicyclopentane derivatives | 伊卡根有限责任公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-28 | — | — | US | disclosed |
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023158584-A1 | NEW BICYCLOPENTANE DERIVATIVES | ICAGEN, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| EP-4172140-A1 | CYCLOBUTYL-UREA DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2023-05-03 | — | — | EP | disclosed |
| CN-115702141-A | Cyclobutyl-urea derivatives | 爱杜西亚药品有限公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-113508109-B | Substituted heterocyclic amide compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-02-10 | — | — | CN | disclosed |
| US-20080139640-A1 | Hydroxamates, Their Manufacture And Use As Pharmaceutical Agents | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
| US-7273866-B2 | 2-aryl thiazole derivatives as KCNQ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| CN-1964963-A | Hydroxamates, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | CN | disclosed |
| CN-1646493-A | 5HT2cReceptor modulators | ARENA PHARM INC (US) | 2005-07-27 | — | — | CN | disclosed |
| US-6831080-B2 | E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-14 | — | — | US | disclosed |
| US-20040147401-A1 | 2-aryl thiazole derivatives as KCNQ modulators | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004060281-A2 | 2-ARYL THIAZOLE DERIVATIVES AS KCNQ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| US-5028256-A | Metolachlor and an acylamide compound, for maize or sorghum | CIBA-GEIGY CORPORATION (US) | 1991-07-02 | — | — | US | disclosed |
| US-4897109-A | ACYLAMINE DERIVATIVE | CIBA-GEIGY CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002452-A1 | BICYCLOPENTANE DERIVATIVES | BICRA, C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A2 4227/4885SLC6A4 4133/4885GPR139 772/4885 |
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | KCNA4, KCNMB4, KCNA7 | SLC6A2 3599/4885SLC6A4 2283/4885GPR139 2801/4885 |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | SLC6A2 1495/4885SLC6A4 1115/4885GPR139 315/4885 |
| US-20080139640-A1 | Hydroxamates, Their Manufacture And Use As Pharmaceutical Agents | HCAR3, HCAR1, HCAR2 | SLC6A2 1252/4885SLC6A4 530/4885GPR139 1912/4885 |
| US-20040147401-A1 | 2-aryl thiazole derivatives as KCNQ modulators | KCNJ2, KCNT1, KCNQ1 | SLC6A2 1127/4885SLC6A4 766/4885GPR139 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.